Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Dysplasia 1Sarcoma, Alveolar Soft Part 1Papillomavirus Infections 1Carcinoma in Situ 1

Interventions

Platinum 2Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 2Cisplatin 2Biopsy 21,2-diaminocyclohexaneplatinum II citrate 2rocakinogene sifuplasmid 1fludarabine phosphate 1fludarabine 1durvalumab 1alovudine 1aldesleukin 1Vaccines, Synthetic 1VGX-3100 1Sonazoid 1Respiratory Function Tests 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1Radiosurgery 1Prochlorperazine 1Positron-Emission Tomography 1Ondansetron 1O(6)-codeine methyl ether 1Meperidine 1Magnetic Resonance Imaging 1MEDI0457 1Loperamide 1Interleukin-2 1Innovar 1Indomethacin 1Immunoglobulin G 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Vulvar Neoplasms × Diphenoxylate × Clear all
NCT02858310 2026-03-09

E7 TCR T Cells for Human Papillomavirus-Associated Cancers

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
224 enrolled 15 charts
Gynecologic

Carcinoma in Situ, Uterine Cervical Dysplasia, Vulvar Diseases, Vulvar Neoplasms, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡